natgillin/translations-raw huggingface dataset:
Neither new or clinically meaningful worsening of nephrocalcinosis nor ectopic mineralisation have been observed in clinical trials of patients with XLH treated with burosumab to achieve normal serum phosphate levels.
U kliničkim ispitivanjima provedenim u bolesnika s XLH-om koji su liječeni burosumabom kako bi se postigle normalne razine fosfata u serumu, nisu opažena nova ili klinički značajna pogoršanja nefrokalcinoze ili ektopične mineralizacije.
Periodic measurement of post prandial serum phosphate is advised.
Savjetuje se periodički mjeriti koncentraciju fosfata u serumu poslije jela.
Name and address of the manufacturer(s) of the biological active substance(s)
Naziv(i) i adresa(e) proizvođača biološke(ih) djelatne(ih) tvari Kyowa Kirin Co., Ltd.
Each vial contains 20 mg burosumab in 1 ml of solution.
Jedna bočica sadrži 20 mg burosumaba u 1 mL otopine.
CRYSVITA should be given by injection under the skin in the arm, abdomen, buttock or thigh by your doctor or a trained healthcare provider.
Lijek CRYSVITA davat će Vam liječnik ili za to osposobljen zdravstveni radnik, injekcijom pod kožu nadlaktice, trbuha, stražnjice ili bedra.
RGI-C Global Score LS Mean score (SE)
Opći rezultat RGI-C-a Srednja vrijednost rezultata dobivena metodom najmanjih kvadrata (SE)
CRYSVITA 20 mg solution for injection
CRYSVITA 20 mg otopina za injekciju
Name and address of the manufacturer(s) responsible for batch release
Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet Piramal Healthcare UK Limited
Each vial contains 30 mg burosumab in 1 ml of solution.
Jedna bočica sadrži 30 mg burosumaba u 1 mL otopine.
Each vial contains 10 mg burosumab in 1 ml of solution.
Jedna bočica sadrži 10 mg burosumaba u 1 mL otopine.
What is CRYSVITA used for
Za što se CRYSVITA koristi
CRYSVITA 10 mg solution for injection
CRYSVITA 10 mg otopina za injekciju
CRYSVITA 30 mg solution for injection
CRYSVITA 30 mg otopina za injekciju
How much CRYSVITA you will be given
Koliko ćete primiti lijeka CRYSVITA
Study UX023-CL201
Ispitivanje UX023-CL201
Study UX023-CL205
Ispitivanje UX023-CL205
CRYSVITA 30 mg injection burosumab
CRYSVITA 30 mg otopina za injekciju burosumab
CRYSVITA 20 mg injection burosumab
CRYSVITA 20 mg injekcija burosumab s.c.
CRYSVITA 10 mg injection burosumab
CRYSVITA 10 mg injekcija burosumab s.c.
CRYSVITA 20 mg solution for injection burosumab
CRYSVITA 20 mg otopina za injekciju burosumab
CRYSVITA 10 mg solution for injection burosumab
CRYSVITA 10 mg otopina za injekciju burosumab
Dizziness may occur following administration of burosumab.
Nakon primjene burosumaba može se pojaviti omaglica.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE 10 mg BOČICA
+1.56 (0.1) (p<0.0001)
+1,56 (0,1) (p<0,0001) +1,58 (0,1) (p<0,0001)
+1.66 (0.1) (p<0.0001)
+1,66 (0,1) (p<0,0001) +1,47 (0,1) (p<0,0001)
64 -1.00 (0.1) (p<0.0001)
-1,00 (0,1) (p<0,0001) -0,84 (0,1) (p<0,0001)
EMA/249807/2015 EMEA/H/C/004009
24. travnja 2015. EMA/249807/2015 EMEA/H/C/004009
It was to be available as gastroresistant capsules (capsules whose contents are not broken down in the stomach and release the medicine in the intestine) containing 30 or 60 mg of duloxetine.
Dostupan je kao gastrorezistetne kapsule (kapsule čiji se sastav ne razgrađuje u želucu i otpušta lijek u crijevima) sadržavajući 30 ili 60 mg duloksetina.
In its letter notifying the Agency of the withdrawal of application, the company stated that it was withdrawing its application because of the identification of GCP issues.
U svojem dopisu kojim je obavijestila Agenciju o povlačenju, tvrtka je navela da povlači svoj zahtjev zbog problema s identifikacijom problema povezanih sa GCP-om.
The application was withdrawn after the CHMP had evaluated the initial documentation provided by the company and formulated a list of questions.
Zahtjev je povučen nakon što je CHMP ocijenio početnu dokumentaciju koju je proizvođač dostavio te je sastavio popis pitanja.
It works by preventing the neurotransmitters serotonin and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.
Djeluje sprečavajući neurotransmitere serotonin i noradrenalin od ponovne apsorpcije u živčane stanice u mozgu i leđnoj moždini.
Duloxetine Sandoz was to be used to treat major depression, pain due to diabetic peripheral neuropathy (damage to the nerves in the extremities that can occur in patients with diabetes) and generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).
Duloxetine Sandoz trebao se koristiti za liječenje velike depresije, boli uslijed dijabetske periferne neuropatije (oštećenja živaca u ektremitetima koje može nastupiti u bolesnika s dijabetesom) i generaliziranog anksioznog poremećaja (dugoročne anksioznosti ili nervoze uslijed svakodnevnih problema).
This means that Duloxetine Sandoz is similar to a ‘reference medicine' already authorised in the European Union (EU) called Cymbalta.
To znači da je Duloxetine Sandoz sličan „referentnom lijeku” koji je već odobren u Europskoj uniji pod nazivom Cymbalta.
On 08 April 2015, Sandoz GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Duloxetine Sandoz, for the treatment of depression, diabetic nerve pain and generalised anxiety disorder.
Dana 08. travnja 2015., proizvođač Sandoz GmbH službeno je obavijestio Odbor za humane lijekove (CHMP) kako želi povući svoju prijavu za odobrenje za stavljanje u promet za Duloxetine Sandoz, lijek za liječenje depresije, dijabetske živčane boli i generaliziranog anksioznog poremećaja.
Duloxetine Sandoz was developed as a ‘generic medicine'.
Duloxetine Sandoz razvijen je kao „generički lijek”.
Because Duloxetine Sandoz is a generic medicine, the company had presented results of tests to determine that Duloxetine Sandoz is bioequivalent to the reference medicine, Cymbalta.
Budući da je Duloxetine Sandoz generički lijek, tvrtka je dostavila rezultate testova kako bi se utvrdilo da je lijek Duloxetine Sandoz bioekvivalentan s referentnim lijekom, Cymbalta.
The company had not yet responded to the questions at the time of the withdrawal.
U trenutku povlačenja proizvođač još nije dostavio svoje odgovore.
mood and reducing the sensation of pain, blocking their re-uptake into nerve cells can improve the symptoms of depression, anxiety and neuropathic pain.
Budući da su neurotransmiteri uključeni u održavanje dobrog raspoloženja i smanjivanje osjećaja boli, inhibirajući njihov ponovni unos u živčane stanice poboljšavaju se simptomi depresije, anksioznosti i neuropatske boli.
Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns about whether the two studies conducted to show bioequivalence between the medicine and the reference product had been carried out in accordance with guidelines for Good Clinical Practice (GCP) and was of the provisional opinion that Duloxetine Sandoz could not have been approved for the treatment of depression, diabetic nerve pain and generalised anxiety disorder.
Na temelju pregleda podataka, u trenutku povlačenja, CHMP imao je razloga za zabrinutost vezano uz dva ispitivanja provedena kako bi se dokazala da je bioekvivaletnost između lijeka i referentnog lijeka provedena u skladu sa smjernicama za dobru klinički praksu (GCP) te da je privremeno mišljenje kao se ne može izdati odobrenje za lijek Duloxetine Sandoz za liječenje depresije, dijabetske živčane boli i generaliziranog poremećaja anksioznosti.
What is Duloxetine Sandoz?
Što je Duloxetine Sandoz?
By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters available for communication between the cells.
Inhibirajući njihov ponovni unos, duloksetin povećava količinu ovih neurotransmitera
The active substance in Duloxetine Sandoz, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor.
Djelatna tvar lijeka Duloxetine Sandoz, duloksetin, je inhibitor ponovnog unosa serotonin noradrenalina.
Duloxetine Sandoz is a medicine that contains the active substance duloxetine.
Duloxetine Sandoz je lijek koji sadrži djelatnu tvar duloksetin.
What was Duloxetine Sandoz expected to be used for?
Za što se Duloxetine Sandoz trebao koristiti?
How is Duloxetine Sandoz expected to work?
Kako je Duloxetine Sandoz trebao djelovati?
Strength Pharmaceutical Form Route of Administration Immediate Packaging
Put primjene Unutarnje pakovanje
This will help prevent dehydration.
To će pomoći u sprečavanju dehidracije.
- Do not throw away any medicines via wastewater (or household waste).
- Nikada nemojte nikakve lijekove bacati u otpadne vode (ili kućni otpad).
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Pažljivo pročitajte cijelu uputu prije nego što počnete primjenjivati ovaj lijek jer sadrži Vama važne podatke.
- The unopened bottle does not require any special storage conditions.
- Neotvorena boca ne zahtijeva posebne uvjete čuvanja.
It is important to try and prevent ONJ developing as it a painful condition that can be difficult to treat.
Važno je nastojati i spriječiti pojavu ONJ jer je to bolno stanje koje može biti teško liječiti.
• in post-menopausal women
• u žena u postmenopauzi
Hypocalcaemia* Uncommon Decreased appetite
Hipokalcijemija * Manje često Smanjen apetit
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Za sve infromacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka u promet:
- After opening the bottle, the product should be used immediately in order to avoid microbial contamination.
- Nakon otvaranja boce, lijek treba odmah primijeniti kako bi se izbjeglo mikrobiološko onečišćenje.
Zoledronic acid Teva Pharma may work for longer than one year, and your doctor will let you know if you need to be treated again.
Zoledronatna kiselina Teva Pharma može djelovati duže od godinu dana, a liječnik će Vam reći ako se trebate ponovo liječiti.
Pharmacotherapeutic group: Drugs for treatment of bone diseases, bisphosphonates, ATC code: M05BA08
Farmakoterapijska skupina: pripravci za liječenje bolesti kostiju, bisfosfonati, ATK oznaka: M05BA08
This is especially important for the elderly (≥ 65 years) and for patients receiving diuretic therapy.
To je osobito važno za starije osobe (≥ 65 godina) i bolesnike koji primaju diuretsku terapiju.
Zoledronic acid was administered once a year, until at least 211 patients in the study population had confirmed clinical fractures.
Zoledronatna kiselina je primijenjena jedanput godišnje dok u barem 211 bolesnika u ispitivanoj populaciji nisu potvrđeni klinički prijelomi.
This is especially important in patients who take diuretics (“water pills”) and in elderly patients (age 65 years or over).
To je osobito važno u bolesnika koji uzimaju diuretike („tablete za mokrenje“) i u starijih bolesnika (u dobi od 65 godina ili više).
• in adult men at increased risk of fracture.
• u odraslih muškaraca s povećanim rizikom od prijeloma.
Adverse reactions, such as dizziness, may affect the ability to drive or use machines.
Nuspojave, kao što je omaglica, mogu utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
• A single dose of Zoledronic acid Teva Pharma should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2).
• Jednokratna doza Zoledronatne kiseline Teva Pharma ne smije biti veća od 5 mg, a trajanje infuzije treba biti najmanje 15 minuta (vidjeti dio 4.2).
Ask your doctor, pharmacist or nurse for advice before using this medicine.
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri za savjet prije nego što primijenite ovaj lijek.
The pack sizes of 5 and 10 are only available as multipacks comprising of 5 or 10 packs, each containing 1 bottle.
Pakiranja sa 5 i 10 boca dostupna su samo kao višestruka pakiranja koja sadrže 5 ili 10 pakiranja, od kojih svako sadrži 1 bocu.
It must not be mixed or given intravenously with any other medicinal products.
Ne smije se miješati ili primjenjivati intravenski s drugim lijekovima.
• Need to ensure appropriate hydration of the patient especially those at an advanced age and those receiving diurectic therapy
• Potrebno je osigurati primjerenu hidraciju bolesnika, osobito onih starije dobi i onih koji primaju terapiju diureticima
Not known** Osteonecrosis of the jaw (see sections 4.4 and 4.8 Class effects)
Nepoznato** Osteonekroza čeljusti (vidjeti dijelove 4.4 i 4.8 Učinci skupine)
• in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture.
• u odraslih muškaraca s povećanim rizikom od prijeloma, uključujući one koji su nedavno imali prijelom kuka nakon manje traume.
Frequency categories are defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Kategorije učestalosti određene su na sljedeći način: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
It is important for your doctor to know all the medicines you are taking, especially if you are taking any medicines known to be harmful to your kidneys (e.g. aminoglycosides) or diuretics (“waterpills”) that may cause dehydration.
Važno je da Vaš liječnik zna za sve lijekove koje uzimate, naročito ako uzimate lijekove za koje je poznato da štetno djeluju na bubrege (npr. aminoglikozidi) ili ako uzimate diuretike (“tablete za mokrenje”) koji mogu uzrokovati dehidraciju.
• Contraindication in pregnancy and in breast-feeding women due to potential teratogenicity
• Kontraindicirana je u trudnica i dojilja zbog moguće teratogenosti
• Patient educational material
• Edukacijskog materijala za bolesnike
You must not be given Zoledronic acid Teva Pharma if you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby.
Zoledronatnu kiselinu Teva Pharma ne smijete primati ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete.
Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.
Zoledronatna kiselina se u provedenim ispitivanjima mutagenosti nije pokazala mutagenom, dok ispitivanje kancerogenosti nije dalo nikakve dokaze o kancerogenom potencijalu.
If you feel dizzy while taking Zoledronic acid Teva Pharma, do not drive or use machines until you feel better.
Ako osjećate omaglicu dok uzimate Zoledronatnu kiselinu Teva Pharma, nemojte upravljati vozilima ili strojevima dok se ne budete osjećali bolje.
After opening: 24 hours at 2°C - 8°C
Nakon otvaranja: 24 sata na 2°C - 8°C
It is currently unclear whether Zoledronic acid Teva Pharma causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received Zoledronic acid Teva Pharma.
Trenutačno nije jasno uzrokuje li Zoledronatna kiselina Teva Pharma te nepravilne otkucaje srca, ali morate se javiti liječniku ako osjetite takve simptome nakon što primite Zoledronatnu kiselinu Teva Pharma.
Other products containing zoledronic acid as an active substance are available for oncology indications.
Ostali lijekovi koji sadrže zoledronatnu kiselinu kao djelatnu tvar dostupni su za onkološke indikacije.
Not known** Hypersensitivity reactions including rare cases of bronchoconstriction, urticaria and angioedema, and very rare cases of anaphylactic reaction/shock
Nepoznato** Reakcije preosjetljivosti uključujući rijetke slučajeve bronhokonstrikcije, urtikarije i angioedema, i vrlo rijetko anafilaktičku reakciju/šok
• Transient increase in serum creatinine may be greater in patients with underlying impaired renal
• Prolazni porast kreatinina u serumu može biti veći u bolesnika koji imaju predležeću oštećenu funkciju bubrega.
For information on the infusion of Zoledronic acid Teva Pharma, see section 6.6.
Za informacije o infuziji Zoledronatne kiseline Teva Pharma vidjeti dio 6.6.
• Physician educational material
• Edukacijskog materijala za liječnike
The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of Zoledronic acid Teva Pharma on an individual patient basis, particularly after 5 or more years of use.
Potrebu za nastavkom liječenja potrebno je ponovno procijeniti periodički na osnovi odnosa koristi i potencijalnih rizika Zoledronatne kiseline Teva Pharma u svakog pojedinačnog bolesnika, a posebno nakon 5 ili više godina primjene.
Zoledronic acid (N=3,875) event rate
Zoledronatna kiselina (N=3875) stopa događaja
Bone histology was evaluated in 7 patients with Paget's disease 6 months after treatment with 5 mg zoledronic acid.
Histologija kostiju procijenjena je u 7 bolesnika s Pagetovom bolešću šest mjeseci nakon liječenja sa 5 mg zoledronatne kiseline.
Zoledronic acid Teva Pharma is also used in patients who have recently broken their hip in a minor trauma such as a fall and therefore are at risk of subsequent bone breaks.
Zoledronatna kiselina Teva Pharma se također koristi u bolesnika koji su nedavno slomili svoj kuk pri maloj traumi kao što je pad pa imaju stoga povećan rizik za sljedeće lomove kosti.
If you are under dental treatment or are due to undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell your dentist that you are being treated with Zoledronic acid Teva Pharma.
Ako ste uslijed liječenja kod zubara ili ako idete na kirurški zahvat zuba (npr. vađenje zuba), obavijestite svog liječnika o Vašem liječenju kod zubara i obavijestite svog zubara da se liječite Zoledronatnom kiselinom Teva Pharma.
While being treated with Zoledronic acid Teva Pharma, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.
Za vrijeme liječenja Zoledronatnom kiselinom Teva Pharma, morate održavati dobru oralnu higijenu (uključujući redovito pranje zuba) i obavljati rutinske preglede kod zubara.
It comes in a clear plastic bottle.
Lijek je dostupan u prozirnim plastičnim bocama.
• Patients, especially elderly patients and those receiving diuretic therapy, should be appropriately hydrated prior to administration of Zoledronic acid Teva Pharma.
• Bolesnici, osobito stariji i oni koji primaju diuretsko liječenje, moraju biti prikladno hidrirani prije primjene Zoledronatne kiseline Teva Pharma.
Zoledronic acid Teva Pharma with food and drink Make sure you drink enough fluids (at least one or two glasses) before and after the treatment with Zoledronic acid Teva Pharma, as directed by your doctor.
Zoledronatna kiselina Teva Pharma s hranom i pićem Pazite da popijete dovoljno tekućine (najmanje jednu ili dvije čaše) prije i nakon liječenja Zoledronatnom kiselinom Teva Pharma, prema uputama liječnika.
Table 2 Summary of vertebral fracture efficacy at 12, 24 and 36 months Outcome
Tablica 2 Sažetak djelotvornosti s obzirom na vertebralne prijelome u 12., 24. i 36. mjesecu Ishod
Tell your doctor and dentist immediately if you experience such symptoms while being treated with Zoledronic acid Teva Pharma or after stopping treatment.
Odmah se obratite svom liječniku i zubaru ako primijetite takve simptome za vrijeme liječenja Zoledronatnom kiselinom Teva Pharma ili nakon prestanka liječenja.
Before stopping Zoledronic acid Teva Pharma therapy If you are considering stopping Zoledronic acid Teva Pharma treatment, please go to your next appointment and discuss this with your doctor.
Prije prestanka uzimanja Zoledronatne kiseline Teva Pharma Ako razmišljate o prekidu liječenja Zoledronatnom kiselinom Teva Pharma, molimo dođite na sljedeći termin i o toj odluci razgovarate sa svojim liječnikom.
Zoledronic acid Teva Pharma is not recommended for anyone under 18 years of age.
Zoledronatna kiselina Teva Pharma ne preporuča se osobama mlađima od 18 godina.
The incidence of delayed hip fracture healing was comparable between zoledronic acid (34 [3.2%]) and placebo (29 [2.7%]).
Incidencija odgođenog zarastanja prijeloma kuka bila je usporediva za zoledronatnu kiselinu (34 [3,2%]) i placebo (29 [2,7%]).
For the treatment of post-menopausal osteoporosis, osteoporosis in men and the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy, the recommended dose is a single intravenous infusion of 5 mg Zoledronic acid Teva Pharma administered once a year.
Za liječenje osteoporoze u postmenopauzi, osteoporoze u muškaraca i liječenje osteoporoze povezane s dugotrajnim liječenjem sistemskim glukokortikoidima, preporučena doza je jednokratna intravenska infuzija od 5 mg Zoledronatne kiseline Teva Pharma primijenjena jedanput u godini dana.
Your doctor, pharmacist or nurse knows how to store Zoledronic acid Teva Pharma properly.
Vaš liječnik, ljekarnik ili medicinska sestra znaju kako pravilno čuvati Zoledronatnu kiselinu Teva Pharma.
Zoledronic acid Teva Pharma works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone.
Zoledronatna kiselina Teva Pharma djeluje tako što vraća proces preoblikovanja kosti u normalu osiguravajući stvaranje normalne kosti, čime kosti postaju snažnije.
Microcomputed tomography (μCT) analysis demonstrated increased trabecular bone volume and preservation of trabecular bone architecture in patients treated with zoledronic acid compared to placebo.
Analiza mikrokompjuteriziranom tomografijom (μCT) pokazala je povećani volumen trabekularne kosti i očuvanje arhitekture trabekularne kosti u bolesnica liječenih zoledronatnom kiselinom u usporedbi s onima koje su primale placebo.
• Need to calculate creatinine clearance based on actual body weight using the Cockcroft-Gault formula before each treatment with Zoledronic acid Teva Pharma
• Potrebno je izračunati klirens kreatinina na temelju stvarne tjelesne težine korištenjem Cockcroft-Gaultove formule prije svakog liječenja Zoledronatnom kiselinom Teva Pharma
Patients being treated with Zoledronic acid Teva Pharma should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Bolesnici koji se liječe Zoledronatnom kiselinom Teva Pharma ne smiju se istovremeno liječiti tim lijekovima ili nekim drugim bisfosfonatima jer nisu poznati kombinirani učinci tih lijekova.
At 24 months a similar significant increase of 3.6% in total hip BMD was observed for patients treated with zoledronic acid as compared to the effects observed in postmenopausal women in the HORIZON-PFT study.
Nakon 24 mjeseca zapaženo je slično značajno povećanje od 3,6% BMD-a cijelog kuka u bolesnika liječenih zoledronatnom kiselinom u usporedbi s učincima zapaženima u žena u postmenopauzi u ispitivanju HORIZON-PFT.
Special populations Patients with renal impairment
Posebne populacije Bolesnici s oštećenjem funkcije bubrega
Follow all instructions given to you by your doctor, pharmacist or nurse carefully before you are given Zoledronic acid Teva Pharma.
Pažljivo slijedite sve upute koje Vam je dao Vaš liječnik, ljekarnik ili medicinska sestra prije nego što počnete uzimati Zoledronatnu kiselinu Teva Pharma.
Talk to your doctor, pharmacist or nurse before you are given Zoledronic acid Teva Pharma: - if you are being treated with any medicine containing zoledronic acid, which is also the active substance of Zoledronic acid Teva Pharma (zoledronic acid is used in adult patients with certain types of cancer to prevent bone complications or to reduce the amount of calcium).
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primite Zoledronatnu kiselinu Teva Pharma: - ako se liječite bilo kojim lijekom koji sadrži zoledronatnu kiselinu, koja je također djelatna tvar u Zolenodratnoj kiselini Teva Pharma (zoledronatna kiselina se koristi u odraslih bolesnika s određenim tipovima raka kako bi se spriječile komplikacije s kostima ili smanjenje udjela kalcija). - ako imate ili ste imali problema s bubrezima.